Rodyti trumpą aprašą

dc.contributor.authorZaleskis, Gintaras
dc.contributor.authorBosas, Paulius
dc.contributor.authorUlys, Albertas
dc.contributor.authorDabkevičienė, Daiva
dc.contributor.authorDarulytė, Neringa
dc.contributor.authorHudson, Bret Andrew
dc.contributor.authorPašukonienė, Vita
dc.date.accessioned2023-09-18T16:08:03Z
dc.date.available2023-09-18T16:08:03Z
dc.date.issued2021
dc.identifier.other(PMID)33744875
dc.identifier.urihttps://etalpykla.vilniustech.lt/handle/123456789/111545
dc.description.abstractOBJECTIVES: The aim of this study was to compare prostate-specific antigen (PSA) kinetics - half-life time (HT), doubling time (DT), and elimination rate PSA (ePSA) in prostate cancer (PCa) monitoring. Implementation of ePSA in clinical practice could help simplify patient monitoring in the remission phase. MATERIALS AND METHODS: A total of 49 PCa patients were examined by their PSA tests before prostatectomy and after 30 days, 91 days, and 24 months. Conventional PSA rate of change parameters (HT and DT) were compared to a new clinically understandable ePSA parameter. RESULTS: We observed that implementation of inverse value (ePSA) rather than HT or DT has distinct advantages: (1) values are valid when PSA is unchanged (ePSA equals zero), (2) the concept of ePSA can be easily understood, as it is a growth fraction, (3) ePSA fluctuates within a narrow range and is thus easy to interpret, and (4) there are no mathematical flaws (no positive skewing). CONCLUSION: Exploring ePSA norm as ≤0% could help spot biochemical recurrence in a timely manner. Primary health care providers tend to use an irrelevant PSA threshold, that is, 4.0 ng/mL, in postoperative follow-up. The delayed referrals of patients in remission might be reduced if ePSA testing is adopted.eng
dc.formatPDF
dc.format.extentp. 292-296
dc.format.mediumtekstas / txt
dc.language.isoeng
dc.relation.isreferencedbyScience Citation Index Expanded (Web of Science)
dc.relation.isreferencedbyScopus
dc.relation.isreferencedbyPubMed
dc.rightsLaisvai prieinamas internete
dc.source.urihttps://talpykla.elaba.lt/elaba-fedora/objects/elaba:100321543/datastreams/MAIN/content
dc.titleA refinement of clinical tumor marker monitoring: Why not use an inverse value of doubling time?
dc.typeStraipsnis Web of Science DB / Article in Web of Science DB
dcterms.accessRightsThis is an Open Access article licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense), applicable to the online version of the article only. Usage and distribution for commercial purposes requires written permission.
dcterms.licenseCreative Commons – Attribution – NonCommercial – 4.0 International
dcterms.references13
dc.type.pubtypeS1 - Straipsnis Web of Science DB / Web of Science DB article
dc.contributor.institutionNacionalinis vėžio institutas
dc.contributor.institutionNacionalinis vėžio institutas Vilniaus universitetas
dc.contributor.institutionInnovita Research, Ltd., Vilnius
dc.contributor.institutionNacionalinis vėžio institutas Vilniaus Gedimino technikos universitetas
dc.contributor.facultyFundamentinių mokslų fakultetas / Faculty of Fundamental Sciences
dc.subject.researchfieldN 010 - Biologija / Biology
dc.subject.researchfieldM 001 - Medicina / Medicine
dc.subject.researchfieldN 004 - Biochemija / Biochemistry
dc.subject.researchfieldN 002 - Fizika / Physics
dc.subject.vgtuprioritizedfieldsFM0202 - Ląstelių ir jų biologiškai aktyvių komponentų tyrimai / Investigations on cells and their biologically active components
dc.subject.ltspecializationsL105 - Sveikatos technologijos ir biotechnologijos / Health technologies and biotechnologies
dc.subject.encancer relapse
dc.subject.enprostate cancer
dc.subject.enprostate-specific antigen
dc.subject.entumor markers
dcterms.sourcetitleMedical principles and practice : international journal of the Kuwait University, Health Science Centre
dc.description.issueiss. 3
dc.description.volumevol. 30
dc.publisher.nameKarger
dc.publisher.cityBasel
dc.identifier.doi33744875
dc.identifier.doi000668636000011
dc.identifier.doi10.1159/000515977
dc.identifier.elaba100321543


Šio įrašo failai

Thumbnail

Šis įrašas yra šioje (-se) kolekcijoje (-ose)

Rodyti trumpą aprašą